Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood test may spot hidden infections in kids with cancer

NCT ID NCT02417168

Diagnosis Sponsor: CAMC Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This pilot study asks whether a blood marker called procalcitonin can help predict bacteremia—a serious bacterial infection in the blood—in children with cancer who develop a fever. Currently, doctors rely on blood cultures, which can take up to 48 hours or give false negatives. The study will measure procalcitonin levels at admission, 12 hours, and 24 hours later in febrile pediatric oncology patients, with and without neutropenia, to see if elevated levels point to bacteremia. If successful, this could lead to fewer hospitalizations and less unnecessary antibiotic treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Procalcitonin level measurement
What this could lead to
If procalcitonin reliably predicts bacteremia, it could help doctors identify serious infections faster, potentially reducing unnecessary hospital stays and antibiotic use in children with cancer.
What could go wrong
This is a very small pilot study, so results may not be conclusive. Procalcitonin may not accurately distinguish bacterial from non-bacterial fevers in all cases, and the findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1 person

The number who actually took part.

Started

Jul 2015

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children between the ages of birth to seventeen years who have an existing oncologic diagnosis and who present with fever to Charleston Area Medical Center Women and Children's Hospital

Ages

Up to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children between the ages of birth to seventeen years. * Present to Charleston Area Medical Center Women and Children's Hospital * Existing pediatric oncology diagnosis. * Temperature greater than 38.0 C or 100.5 Fahrenheit. * Central venous access or functional port available. Exclusion Criteria: * Any non-pediatric (eighteen years and above) oncology patient or a non-oncology patient. * The patient does not have central venous access or a port from which the blood can be drawn.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia Cancer

Contacts and locations

Locations

  • CAMC Health Systems

    Charleston, West Virginia, 25304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.